Categories AlphaGraphs, Earnings, Health Care

Earnings: Regeneron Pharmaceuticals (REGN) Q1 profit falls; revenue up 7%

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on Thursday reported a decline in adjusted earnings for the first quarter of 2023, despite an increase in revenues.

Regeneron Q1 2023 earnings infographic

Total revenues moved up 7% year-over-year to $3.16 billion in the three months ended March 2023. Excluding Ronapreve, revenues came in at $2.94 billion.

Meanwhile, the biotechnology firm’s first-quarter adjusted earnings dropped to $10.09 per share from $11.49 per share in the same period of 2022. Unadjusted profit was $818 million or $7.17 per share, compared to $974 million or $8.61 per share last year.

“We remain focused on advancing our robust pipeline at all stages, and we were pleased to announce positive data from a late-stage study of Dupixent in COPD and make continued progress with our costimulatory and bispecific antibody candidates in oncology,” said the company’s CEO Leonard Schleifer.

Prior Performance

  • Regeneron Pharmaceuticals Q4 2022 earnings infographic

Most Popular

Key metrics from Kroger’s (KR) Q3 2025 earnings results

The Kroger Co. (NYSE: KR) reported its third quarter 2025 earnings results today. Total company sales rose to $33.9 billion from $33.6 billion in the same period last year. Identical

Dollar General (DG) Q3 2025 Earnings: Key financials and quarterly highlights

Dollar General Corporation (NYSE: DG) reported its third quarter 2025 earnings results today. Net sales increased 4.6% year-over-year to $10.65 billion. Same-store sales increased 2.5%. Net income was $282.7 million, or

HRL Earnings: All you need to know about Hormel Foods’ Q4 2025 earnings results

Hormel Foods Corporation (NYSE: HRL) reported its fourth quarter 2025 earnings results today. Net sales increased 1.5% year-over-year to $3.18 billion. Organic sales were up 2%. Net loss attributable to Hormel

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top